Findings from a landmark clinical trial in pediatric Crohn's disease show a clear benefit of adding methotrexate to treatment with the tumor necrosis factor inhibitor (TNFi) adalimumab (Humira), but ...
Please provide your email address to receive an email when new articles are posted on . Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback